News
NVCR
22.48
+3.55%
0.77
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Simply Wall St · 3d ago
Weekly Report: what happened at NVCR last week (0203-0207)?
Weekly Report · 5d ago
Weekly Report: what happened at NVCR last week (0127-0131)?
Weekly Report · 02/03 09:22
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'
Benzinga · 01/30 13:46
Weekly Report: what happened at NVCR last week (0120-0124)?
Weekly Report · 01/27 09:23
Novocure opens new global headquarters in Switzerland
TipRanks · 01/22 10:15
NovoCure (NVCR) Gets a Buy from Piper Sandler
TipRanks · 01/21 11:48
Weekly Report: what happened at NVCR last week (0113-0117)?
Weekly Report · 01/20 09:21
Deep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings)
Benzinga · 01/14 13:01
Novocure Price Target Maintained With a $38.00/Share by HC Wainwright & Co.
Dow Jones · 01/14 12:48
HC Wainwright & Co. Reiterates Buy on NovoCure, Maintains $38 Price Target
Benzinga · 01/14 12:37
NovoCure’s Strong Revenue Growth and Strategic Advancements Support Buy Rating
TipRanks · 01/14 11:26
NovoCure’s Strong U.S. Revenue and European Growth Reinforce Buy Rating Despite Mixed Regional Performance
TipRanks · 01/14 01:07
Novocure anticipates higher-than-expected 2024 revenues
Seeking Alpha · 01/13 14:10
Novocure sees Q4 revenue $161.3M, consensus $153.05M
TipRanks · 01/13 12:20
Novocure sees FY24 revenue $605.2M, consensus $596.95M
TipRanks · 01/13 12:20
Novocure Reports Preliminary Net Revenues For Q4 Of $161.3M, Up 21% YoY Compared To Consensus Of $153.052M
Benzinga · 01/13 12:16
Novocure Reports Preliminary Net Revenues For FY2024 Of $605.2M, Up 19% YoY Compared To Consensus Of $594.9M
Benzinga · 01/13 12:15
Weekly Report: what happened at NVCR last week (0106-0110)?
Weekly Report · 01/13 09:22
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
Barchart · 01/13 06:00
More
Webull provides a variety of real-time NVCR stock news. You can receive the latest news about Novocure through multiple platforms. This information may help you make smarter investment decisions.
About NVCR
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.